Abstract:The chromatin remodeling gene AT-rich interactive domain-containing protein 1A (ARID1A) encodes the protein BAF250a, a subunit of human SWI/SNF-related complexes. Recent studies have identified ARID1A as a tumor suppressor. Here, we show that ARID1A expression is reduced in gastric cancer (GC) tissues, which are significantly associated with local lymph node metastasis, tumor infiltration and poor patient prognosis. ARID1A silencing enforces the migration and invasion of GC cells, whereas ectopic expression of ARID1A inhibits migration. The adhesive protein E-cadherin is remarkably downregulated in response to ARID1A silencing, but it is upregulated by ARID1A overexpression. E-cadherin overexpression significantly inhibits GC cell migration and invasion, whereas CDH1 (coded E-cadherin) silencing promotes migration. Restored expression of CDH1 in ARID1A-silenced cell lines restores the inhibition of cell migration. Luciferase reporter assays and chromatin immunoprecipitation indicate that the ARID1A-associated SWI/SNF complex binds to the CDH1 promoter and modulates CDH1 transcription. ARID1A knockdown induces evident morphological changes of GC cells with increased expression of mesenchymal markers, indicating an epithelial-mesenchymal transition. ARID1A silencing does not alter the level of beta-catenin but induces a subcellular redistribution of beta-catenin from the plasma membrane to the cytoplasm and nucleus. Immunohistochemical studies demonstrate that reduced expression of E-cadherin is associated with local lymph node metastasis, tumor infiltration and poor clinical prognosis. ARID1A and E-cadherin expression show a strong correlation in 75.4% of the analyzed GC tissues. They are synergistically downregulated in 23.5% of analyzed GC tissues. In conclusion, ARID1A targets E-cadherin during the modulation of GC cell migration and invasion.

Tumor suppressor role of chromatin-remodeling factor ARID1A]

Research Progress of the Tumor Suppressor ARID1A

Advances in research on ARID1 A in Malignancies

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

ARID1A is Downregulated in Non-Small Cell Lung Cancer and Regulates Cell Proliferation and Apoptosis

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer

ARID1A Deficiency Weakens BRG1-RAD21 Interaction That Jeopardizes Chromatin Compactness and Drives Liver Cancer Cell Metastasis.

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.

Chromatin Remodeling Gene AT-rich Interactive Domain-Containing Protein 1A Suppresses Gastric Cancer Cell Proliferation by Targeting PIK3CA and PDK1.

Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner

ARID1A in Gynecologic Precancers and Cancers

ARID1A regulates R-loop associated DNA replication stress

Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.

Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors

Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency

Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer